ImprovedHelicobacter pyloriEradication Rate of Tailored Triple Therapy by AddingLactobacillus delbrueckiiandStreptococcus thermophilusin Northeast Region of Thailand: A Prospective Randomized Controlled Clinical Trial
Background and Aim. To evaluate the effect ofLactobacillus delbrueckiisubsp.bulgaricusandStreptococcus thermophilustoHelicobacter pylorieradication in different periods of therapeutic protocol.Methods. Infected patients were randomized to one-week tailored triple therapy (esomeprazole 20 mg bid, clarithromycin 500 mg bid/metronidazole 400 mg tid if clarithromycin resistant, and amoxicillin 1000 mg bid) with placebo (group 1,n=100); one week of pretreatment with probiotics (group 2,n=100); and one week of pretreatment with probiotic followed by one week of the same probiotics after treatment (group 3,n=100).Result. PP analysis involved 292 patients, 98 in group 1, 97 in group 2, and 97 in group 3. Successful eradication was observed in 229 patients; by PP analysis, the eradication rates were significantly higher (P<0.01, 95% CI; 0.71–0.97) in group 2 and group 3 than group 1. ITT analysis eradication rates were significantly higher in group 2 and group 3 than group 1 (P<0.0195% CI; 0.72–0.87), and there is no significant difference between the three groups (P=0.32) in terms of adverse events.Conclusion. Adding probiotics before or before and after tailored treatment can improveHelicobacter pylorieradication rates. This trial is registered with Thai Clinical Trials Registry number:TCTR20141209001.